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Abstract
Cesarean scar pregnancy (CSP) and cervical pregnancy are categorized as 
non-tubal ectopic pregnancy, because these are associated with a high burden of 
maternal and fetal morbidity including early uterine rupture, prevalence of pla-
centa previa accrete spectrum, massive hemorrhage, and hysterectomy. Although 
management methods vary according to the week of gestation, recent reviews 
and reports support an interventional or a combination of surgical and medical 
approaches for treatment of unruptured CSP and cervical pregnancy rather than 
medical approach alone. In cases of massive hemorrhage, pressure hemostasis 
using balloon tamponade should first be performed. If such hemostasis proves to be 
ineffective, surgical excision or transcatheter arterial embolization (TAE) should be 
selected next. TAE reportedly achieves a high hemostasis rate. However, complica-
tions such as subsequent endometrial hypoplasia, menstruation disorder, infertility, 
placenta accreta, and uterine rupture have been reported, even in cases that have 
undergone successful hemostasis with TAE using an absorbable embolus. Recently, 
a minimally invasive hemostatic strategy in obstetrics, which aims to preserve 
uterine function and enhance the safety of subsequent pregnancies, has been devel-
oped. Therefore, we should reconsider uterus-preserving hemostatic strategies for 
critical hemorrhage and management of non-tubal ectopic pregnancy under these 
circumstances by using safe and minimally invasive treatment modalities.
Keywords: arterial embolization, balloon tamponade, cervical pregnancy, cesarean 
scar pregnancy, massive hemorrhage, methotrexate
1. Introduction
Cesarean scar pregnancy (CSP) and cervical pregnancy are categorized as  
non-tubal ectopic pregnancy and may cause massive hemorrhage, uterine rupture, 
and hysterectomy. In CSP and cervical pregnancy cases, it is possible that the 
location of the gestational sac (GS) may lead to a misdiagnosis of abortion. Another 
possibility is a failure to detect CSP until massive hemorrhage occurs following 
curettage. Therefore, diagnosis and treatment strategies in early pregnancy are 
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important. Delay in the diagnosis and management may lead to massive hemor-
rhage, which is difficult to control. This complication can be treated with life-saving 
hysterectomy or uterine arterial embolization, which requires massive blood 
transfusion [1]. Management based on the pathophysiology of the implantation 
site that has a rich blood supply is essential. Although management methods vary 
according to the week of gestation, typical strategies include surgical treatment, 
administration of drugs such as methotrexate (MTX), and combinations of these 
treatments. In addition, hemostatic procedures vary and include balloon tampon-
ade, transcatheter arterial embolization (TAE), and surgical treatments such as 
curettage, evacuation, wedge resection, and hystero-resectoscopy, for control and 
prevention of hemorrhage.
In the field of obstetrics, TAE is known to be highly effective in controlling 
uterine hemorrhage and hematoma. This procedure reportedly achieves a high 
hemostasis rate, and thus, the frequency of hysterectomy has sharply decreased [2, 3]. 
However, complications such as subsequent endometrial hypoplasia, menstruation 
disorder, infertility, pregnancy loss, placenta accreta, and uterine rupture have been 
reported, even in cases that have undergone successful hemostasis with TAE using 
an absorbable embolus [4–6]. Recently, a minimally invasive hemostatic strategy 
in obstetrics, which aims to preserve uterine function and enhance the safety of 
subsequent pregnancies, has been developed [2, 7]. Therefore, we should reconsider 
uterus-preserving hemostatic strategies for critical hemorrhage and management of 
non-tubal ectopic pregnancy under these circumstances by using safe and minimally 
invasive treatment modalities. We herein discuss how to select the optimal hemostatic 
strategy and its management based on literatures and our experiences of non-tubal 
ectopic pregnancy.
2. Pathology and frequency
When the uterus is observed by ultrasonography more than 3 months after 
cesarean section (by transverse incision in the lower uterine segment), endometrial 
defect and defect or thinning of the myometrium at the site of the uterine incision are 
recognized as a triangular echo-free space at a frequency of approximately 50% [8].
Implantation at this site is considered to be the origin of CSP [9]. Delay in the 
diagnosis and treatment of CSP may cause uterine rupture and massive hemor-
rhage, resulting in hysterectomy or massive blood transfusion in serious cases. 
In the case of CSP, the site of villous anchoring is the isthmus of the uterus or the 
cervical canal where the endometrium and cervical mucosa are thinner than in the 
uterine body. Therefore, chorionic villi are likely to penetrate into the myometrium, 
inducing conditions similar to placenta increta and placenta percreta. The clinical 
picture and course vary according to the site of villous anchoring [1].
It has been reported that the frequency of CSP is 0.04–0.19% among all preg-
nancies, 0.15% among those with prior cesarean section, and 6.1% among ectopic 
pregnancies associated with prior cesarean section [10]. Recently, a national cohort 
study showed that the estimated incidence of CSP was 0.015% in the UK [11]. It 
is speculated that the incidence of CSP may increase in the future as the rate of 
cesarean section rises.
3. Diagnosis
Chorionic villi are smaller and penetrate less deeply into the myometrium 
in the early stages of pregnancy. Therefore, they are considered to be easier 
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to remove, and it is also believed that the uterus is more likely to be preserved, 
in early pregnancy. After 9 or 10 weeks of gestation, the placenta invades the 
myometrium more deeply, and there is abundant blood flow into the placental 
bed, increasing the risk of massive hemorrhage. The risk of uterine rupture and 
placental invasion into the bladder is also increased. When accurately diagnosing 
CSP, it is important to observe the boundary area between the uterine body and the 
cervix in early pregnancy. The decisive factors in making a diagnosis of CSP are the 
presence of a gestational sac (GS) in that area and villous adhesion to the anterior 
wall (Table 1) [1, 8, 12–14]. Transvaginal ultrasonography is useful for identify-
ing the implantation of chorion frondosum in the scar area (Table 2, Figure 1); 
the reported sensitivity of this modality is 84.6% [14]. The combined use of color 
Doppler ultrasonography allows clinicians to estimate the viability of gestational 
tissue [10, 13], providing useful information for selection of the most appropriate 
1. Diagnosis using transvaginal ultrasonography and contrast-enhanced magnetic resonance imaging
• Evaluation of the implantation site
• Evaluation of blood flow around the villous tissue invading the scar area (Figures 2 and 3)
• Evaluation of thinning of the scar area, presence/absence of continuity of the myometrium, and 
presence/absence of villous invasion into the bladder
2. Evaluation of the viability of the villi
• Blood hCG level
• Color Doppler ultrasonography
3. Presence/absence of vaginal bleeding
Table 1. 
Key points in diagnosing cesarean scar pregnancy.
1. There is no gestational sac in the uterine cavity.
2. In the sagittal view of the uterus, thinning and a wedge-shaped defect of the anterior wall myometrium 
are detectable in the wound area of the previous cesarean section, and the gestational sac is present in 
that area.
3. Villi (high echoic area) are observed on the bladder side of the anterior wall of the uterus.
4. Color Doppler ultrasonography shows blood flow in the gestational sac and areas around the scar.
Table 2. 
Ultrasonographic findings of cesarean scar pregnancy.
Figure 1. 
Findings of transvaginal color Doppler ultrasonography (produced with permission from [1]). The gestational 
sac accompanied by blood flow in the surrounding tissues is seen near the scar of the previous cesarean section 




Findings of T2-weighted magnetic resonance imaging (produced with permission from [1]). This is a case 
of cesarean scar pregnancy with positive fetal heartbeats at 9 weeks of gestation. The chorion frondosum is 
bounded on the bladder and extends into the thinned myometrium of the scar.
treatment method. The descending GS in the event of an inevitable abortion and 
GS in CSP can be distinguished by the presence/absence of blood flow in the 
villous area [1]. Magnetic resonance imaging (MRI) is also useful for determin-
ing the thickness of the myometrium in the wound site and the depth of villous 
invasion into the bladder, as well as for identifying nutrient vessels (Figure 2) [1]. 
When invasion into the bladder is suspected in the middle stages of pregnancy or 
thereafter, confirmation by cystoscopy is required.
4. Management of cesarean scar pregnancy (CSP)
Although expectant management of CSP with positive fetal heart activity 
may still be a choice [11, 15], termination of CSP and cervical pregnancy should 
be offered to these women and families as one of the therapeutic options. The 
basic policy for the management of CSP and cervical pregnancy is termination of 
pregnancy and preservation of the uterus, because these are associated with a high 
burden of maternal and fetal morbidity including complicated miscarriage, early 
uterine rupture, prevalence of placenta previa accreta spectrum, massive hemor-
rhage, hysterectomy, maternal and fetal death, etc. The method of treatment should 
be selected according to the gestational week, presence/absence of fetal heart beats, 
the blood hCG level, and abundance of the blood supply adjacent to villi or the 
gestational sac.
Chemotherapeutic drugs such as methotrexate (MTX) are administered sys-
temically or locally, with or without potassium chloride (KCl), to avoid surgical 
treatment for CSP [16–19]. However, achieving the desired healing with drug treat-
ment alone can be time-consuming, and hemorrhage or infection may occur con-
comitantly during the process of treatment. MTX treatment alone as the first-line 
therapy showed low success rate. In addition, adverse reactions to drugs, such as 
stomatitis and leucocytopenia, may also occur. Recent reviews and reports support 
an interventional or a combination of surgical and medical approaches rather than 
medical approach alone [20–24]. In a national cohort study, surgical management 
appears to be associated with a high success rate, low complication rate, and short 
posttreatment follow-up [11].
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If there is a CSP mass protruded toward outside of the uterus (exogenic type) 
(Figure 3), or a mass attached to defect or thinning (<2 mm) of lower uterine 
myometrium, the lesion may be removed laparoscopically or by laparotomy and 
then sutured [25–27], because these types of CSPs could be complicated with 
uterine rupture and bleeding early in pregnancy. But evidence-based treatment still 
remains unclear in these cases.
4.1 Surgical approach
4.1.1 Curettage
Curettage or evacuation allows preservation of fertility, can be performed 
under intravenous or spinal anesthesia, and is minimally invasive [1, 18, 20, 22–25, 
27, 28]. Curettage or evacuation may be performed under ultrasound guide after 
administration of MTX and/or KCl. In addition, it requires only a short period of 
hospitalization in successful cases. On the other hand, there is the risk of massive 
hemorrhage or uterine perforation during surgery as well as complications such as 
uterine rupture and residual tissue. Additional treatment such as balloon compres-
sion hemostasis or TAE may be required to deal with bleeding [27].
It has been reported that massive hemorrhage, difficult to control, occurred 
after curettage in patients who had a low hCG level but had abundant blood flows 
in the lesion, prompting caution in the management of such patients [1]. This is 
because neovascularity may persist even when the hCG level is decreased after villi 
have been devitalized by chemotherapy or dilation and curettage (D&C).
4.1.2 Other surgical procedures
In patients with massive hemorrhage after D&C or with CSP diagnosed after 
massive hemorrhage, priority is given to hemostasis. Therefore, CSP is removed 
by transvaginal resection [26] or laparotomic resection [29], and uterine artery 
ligation [30], cervical suture [31], or TAE is performed. When deep villous invasion 
is predicted in view of the gestational week, the fertilized ovum should be removed 
by abdominal resection and suture in cases with wound rupture or dehiscence or 
subserous protrusion of the lesion.
Along with recent advancements in laparoscopic techniques, cases undergo-
ing less invasive laparoscopic or hysteroscopic resection of the lesion have been 
Figure 3. 
Protrusion of the cesarean scar pregnancy lesion toward the bladder (produced with permission from [1]). The 




reported [14, 18, 20, 22, 23]. Surgical resection of the lesion and wound repair 
(wedge resection and repair) is reportedly less likely to require additional treatment 
and is highly effective for the prevention of recurrence. However, at present, data 
on the scientific basis of treatment and recurrence of CSP are lacking.
5. Management of cervical pregnancy
Several case reports and literatures support surgical therapy alone or in com-
bination with MTX and/or mifepristone rather than medical therapy alone for 
treatment of cervical pregnancy as the same as those of CSP [21, 32–35]. Uterine 
artery embolization for treatment and prevention of hemorrhage during curettage 
or evacuation is also effective to preserve the uterus [36–39].
To control bleeding during curettage and evacuation, hemostatic techniques such 
as hemostatic clamps or cervical cerclage to block cervical blood supply and balloon 
tamponade by Foley catheter or a cervical ripening balloon were reported [40–44]. 
Recently, more minimally invasive total hysteroscopic treatment for cervical preg-
nancy and also conservative treatment, using a cervical ripening double-balloon cath-
eter alone, were reported [44, 45]. These seem to be an effective, safe, and minimally 
invasive and single promising treatment without any medical and surgical treatment. 
These individual managements have to be validated on a large patient population.
6. Control of bleeding
Massive hemorrhage reportedly occurs in some cases after evacuation of the uterus 
D&C has on occasion been performed without an accurate diagnosis. In such cases, 
balloon tamponade, TAE, and surgical treatment are effective management strategies. 
If balloon tamponade or TAE is successful in controlling hemorrhage, conservative 
treatment is also a feasible option. If bleeding is under control, there are several pos-
sible treatment options for preservation of the uterus. These options have their own 
advantages and disadvantages, and selection of the most appropriate treatment varies 
according to the facility and the time of day. Therefore, the treatments should be tai-
lored to individual patients based on the situation and their wishes regarding fertility.
In cases experiencing massive hemorrhage, pressure hemostasis using balloon 
tamponade should first be performed. If such hemostasis proves to be ineffective, 
surgical excision or TAE should be selected next. When performing cesarean scar 
resection, the right and left uterine arteries are to be clamped.
6.1 Balloon tamponade
This is a hemostatic technique used for overall uterine hemorrhage in the 
puerperal period including atonic bleeding, incomplete cervical laceration, crush 
syndrome, and bleeding from the separation surface of placenta previa. Balloon 
tamponade is also effective and useful for uterine hemorrhage from CSP and cervi-
cal pregnancy (Figure 4) [46]. In an emergency, insertion and placement of the 
balloon are technically easy and can be performed expeditiously; this technique is 
simple and minimally invasive. It is also possible to determine within a short period 
of time whether hemostasis can be achieved by tamponade alone (tamponade test) 
[47]. Even when switching to TAE is necessary, the radiology department does not 
need to be consulted, and the amount of bleeding during preparation for TAE can 
be decreased. This technique is also useful for temporary hemostasis when a patient 
must be transferred to an advanced medical facility.
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The balloon should be gently pulled to confirm that it would not easily prolapse 
into the vaginal cavity and that bleeding from the cervical os has been halted. Long 
gauze should be retained in the vaginal cavity to prevent prolapse of the balloon. 
A urethral catheter should be placed in the bladder to prevent urinary retention. If 
there is no massive hemorrhage that would surpass the absorption capacity of the 
retained gauze, the balloon is to be removed in 24–48 h. The presence of uncontrol-
lable bleeding immediately after the insertion should be deemed a negative result 
of the tamponade test, and the procedure is then switched to TAE or laparotomic 
hemostasis without hesitation.
6.2 Transcatheter arterial embolization (TAE)
If bleeding is not controllable by the procedures described above, arterial 
embolization should be performed without hesitation. TAE is advantageous in 
that it allows embolization of not only the artery in question but also anastomotic 
branches while confirming the bleeding point. The rates of hemostasis achievement 
are reportedly in the range of 89–97% [1, 3].
It is known that, in CSP cases, abnormal growth and anastomosis of inflow ves-
sels occur when the shaggy chorion grows not in the uterine body but in the vicinity 
of the site of entry into the uterine artery; this causes pathological features different 
from those associated with the uterine blood flow distribution in normal pregnancy. 
Therefore, unlike the conventional uterine arterial blood flow, vascular anastomo-
ses are not restricted to those derived from the internal iliac artery. Various anasto-
moses involving the external iliac artery, lumbar artery, inferior mesenteric artery, 
sacral artery, superior gluteal artery upstream of the internal iliac artery system, 
and the external iliac artery system are observed.
Figure 4. 
Compression hemostasis by balloon tamponade (produced with permission from [1]). (A) In a case with 
cesarean scar pregnancy, after dilation and curettage, a hematoma (pooling of blood) was observed in the 
wound area, which prominently showed blood spurting out into its cavity. This case is the same as the one at 
9 weeks of gestation in Figure 2. (B) The blood flow disappears after inflation with a Minimetro®. A balloon 
should be inserted from the uterine os guided by ultrasound. Physiological saline (20–30 mL) is then infused 
into the balloon. The balloon should be gently pulled to confirm that it will not easily prolapse into the vaginal 
cavity and that bleeding from the uterine os has been halted. Recently, the bleeding point after dilation and 
curettage could be precisely detected by contrast-enhanced ultrasonography, and a balloon could be inflated at 
the bleeding point until bleeding stops.
Non-tubal Ectopic Pregnancy
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Rebleeding may occur due to recanalization or insufficient embolization, and it 
is difficult to control bleeding when there is abundant blood flow from the external 
iliac artery region. Therefore, attention should be paid to the patient’s general 
condition after implementation of TAE. In most cases, bleeding can be controlled 
by TAE. If TAE is ineffective, or if bleeding persists, it is recommended that the 
aforementioned balloon tamponade be added to the management. Gelatin sponge 
is usually used as a temporary solid embolic substance lasting for several days to 
about 2 weeks. In addition, metal coils as permanent solid embolic substances and 
N-butyl-2-cyanoacrylate as a permanent liquid embolic substance are also available. 
The incidence rate of adverse reactions is 6–7.8%. Fever is the most frequent untow-
ard effect. Other adverse reactions include endometrial necrosis, adhesion, myome-
trial necrosis, ovarian insufficiency, bladder necrosis, gluteal muscle necrosis, and 
pelvic suppuration [1, 3]. Pregnancy after TAE for postpartum hemorrhage may 
be associated with increased risk of obstetric hemorrhage due to placenta accreta 
spectrum. Therefore, precautions in perinatal management are required in manag-
ing the subsequent pregnancy.
6.3 Surgical hemostasis
If bleeding is uncontrollable employing the procedures described above, laparo-
tomic hemostasis should be selected as the last resort. Since TAE became available, 
application of this technique has mostly been limited to cases of uterine rupture in 
the affected area. Hysterectomy, ligation of the uterine artery, or wedge resection 
and repair of the lesion in the scar should be performed. Prompt selection of the 
optimal procedure, taking into consideration the amount of bleeding, size of the 
lesion, whether the patient desires fertility preservation, etc., is necessary. Patients 
with indications for these procedures often have concomitant obstetric coagulopa-
thy. Therefore, sufficient supplementation of coagulation factors is also essential 
prior to surgery [2, 7].
6.4 Treatment of coagulopathy
In cases of massive hemorrhage, patients must be kept in good systemic condi-
tion, and local hemostasis must be achieved while paying attention to the possible 
occurrence of coagulopathy under monitoring of fibrinogen levels as point-of-care 
testing in order to perform early diagnosis and treatment of coagulopathy [7]. When 
coagulopathy is present, local hemostasis, such as balloon tamponade, surgical 
sutures, and TAE, is difficult to achieve because of hemorrhagic tendency. In these 
cases of coagulopathy, the blood fibrinogen level is often <100 mg/dL. Therefore, 
the treatment of coagulopathy should be performed by combined administration 
of concentrated coagulation factors (fibrinogen concentrate and cryoprecipitate) 
and fresh-frozen plasma promptly to obtain a blood fibrinogen level of at least 
150–200 mg/dL [7, 48]. If coagulopathy is eliminated, the conventional hemostatic 
procedures become effective.
7.  A minimally invasive hemostatic strategy in CSP and cervical 
pregnancy
Curettage alone is reportedly not a suitable first-choice procedure because using 
curettage only may lead to serious complications such as massive hemorrhage or 
uterine rupture, necessitating additional treatment in 76.2% (16/21) of patients 
[1]. On the other hand, the methotrexate (MTX) monotherapy is time-consuming 
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in terms of achieving cure and may be accompanied by hemorrhage or infection. 
Reduction of the chorionic tissue by MTX therapy to decrease blood flow, followed 
by curettage or laparotomy, rather than MTX or curettage alone, achieves a higher 
cure rate and is associated with fewer complications such as hemorrhage, infection, 
and sepsis.
For the management of CSP and cervical pregnancy in the first trimester, we 
first perform ultrasonography to confirm the implantation site of the gestational 
sac, observe the status and thickness of the myometrium in surrounding areas and 
the presence/absence of fetal heart beats, and determine the gestational week. At 
the same time, we measure the blood hCG level and evaluate blood flow around the 
gestational sac by Doppler ultrasonography. Changes in the blood hCG levels and 
the status of blood flow are useful for judging the viability of chorionic villi and the 
efficacy of estimating chemotherapy. If there is abundant blood flow in the myome-
trium as well as in the tissues surrounding the gestational sac, villous invasion site 
on the myometrium is suspected. In such cases, implementation of D&C alone is 
expected to cause massive hemorrhage.
When there are fetal heart beats, potassium chloride (KCl) is administered 
directly to the fetus to cause cessation of the heart beating. MTX is administered 
systemically (1 mg/kg body weight) or by local injection to the villous area at the 
same time. Subsequently, MTX is administered systemically every 7–10 days. In 
patients with high blood levels of hCG, MTX therapy used to be performed to 
decrease the hCG level to a target of 20,000 mIU/mL, or even lower, followed by 
TAE and curettage. The rates of blood transfusion and/or blood loss of >2500 mL 
in these combined treatment (MTX + TAE + D&C) were significantly decreased, 
compared with those in D&C alone, 9.5 and 83.3% respectively.
The rate of additional surgical treatment, such as wedge resection or hysterec-
tomy, in combined treatment, was none, compared with D&C alone, 0 and 50.0%, 
respectively. There were no complications such as uterine rupture, postoperative 
infections, menstrual abnormalities, and ovarian dysfunction in D&C alone and 
combined treatment. These combined treatments yielded satisfactory results with 
a decreased volume of blood loss, no additional surgical treatment, and a high cure 
rate, compared with D&C alone (Figure 5, Tables 3 and 4).
Currently, prophylactic TAE before D&C is avoided whenever possible, with the 
aim of preventing short-term complications and uterine rupture in the subsequent 
pregnancy, and also shortening hospital stay. A target blood hCG levels after MTX 
is also changed to <40,000 mIU/mL for adverse effects of MTX. Then, ultrasound-
guided D&C to evacuate the gestational sac is performed a week later after MTX 
therapy. Bleeding point during D&C could be found by contrast-enhanced ultraso-
nography, and a cervical ripening miniballoon (Minimetro®) could be inserted at 
the bleeding point and inflated until bleeding stops [46, 49]. If bleeding continues, 
TAE or laparoscopic wedge resection would be performed as soon as possible. Nine 
patients with CSP (6–12 weeks gestation) and one (7 weeks gestation) with cervi-
cal pregnancy were treated under new management. Seven cases were successfully 
treated with D&C and balloon tamponade after MTX. Additional treatments were 
needed in three cases for bleeding. This combined therapy resulted in all complete 
cure and no additional surgical therapy without complications.
Moreover, if early detection of CSP is possible, more minimally invasive treat-
ments might be another option of treatment such as double balloon conservative 
therapy or hysteroscopic resection without MTX therapy. We also experienced one 
case with CSP to be successfully treated after cessation of fetal heart beats by local 
injection of KCl. She selected conservative therapy without chemotherapy and 
surgical therapy and then was just followed up in outpatient clinic. It took 6 months 
to be cured completely, but there were no complications and no bleeding. Even in 
Non-tubal Ectopic Pregnancy
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Characteristic D&C alone 
(n:6)
MTX + TAE + D&C (n:21) P-value
Age (years) 34.5 + 3.0 34.0 + 5.8 0.84
(32–39) (23–42)
Number of previous CS (n) 1.5 + 0.8 1.3 + 0.6 0.47
(1–3) (1–3)
Gestational age at diagnosis (weeks) 7.8 + 2.4 6.3 + 1.1 0.19
(6–12) (5–8)
Blood hCG levels at diagnosis (mIU/mL) 17,551.3+ 37,876.1+ 0.18
20,483.0 33,816.3
Blood hCG levels at D&C (mIU/mL) 15,360.8+ 17,840.5+ 0.78
20,344.9 19,111.9
There are no significant differences in characteristics between D&C alone and combined treatment.
Table 3. 
Comparison of background between cases with dilation and curettage (D&C) alone and those with 
methotrexate + transcatheter arterial embolization + D&C.
Figure 5. 
Treatment results of cesarean scar pregnancy with fetal heart beats under uterus-preserving management. 
Thirty patients diagnosed with cesarean scar pregnancy with positive fetal heartbeat in the first trimester were 
treated at Saitama Medical Center and Juntendo University Hospital from 1998 to 2010. The average maternal 
age was 33.3 ± 5.8 years (mean ± SD), and average gestational age on admission was 6.6 ± 1.5 weeks of gestation. 
The average hCG level on admission was 29,534 ± 26,284 mIU/mL, and its level on dilation and curettage 
was 19,995 ± 24,765 mIU/mL. Twenty-one patients were treated under our uterus-preserving management 
policy and six patients were transferred to our hospital due to uncontrollable hemorrhage after dilation and 
curettage. This management strategy yielded satisfactory results with a decreased volume of blood loss and a 
high cure rate.
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cases with placenta previa on cesarean delivery scar, who were managed to leave the 
placenta in situ for placenta accreta spectrum disorders after cesarean section near 
term (median 36 weeks gestation; range 28–38 weeks gestation) in order to preserve 
the uterus without hysterectomy, the conservative therapy was successful in 25 
(69.4%) cases without any additional surgery [50]. Placental resorption occurred 
postpartum (median 89 days; range 6–510 days). Hysterectomy was performed for 
the other 11 cases, primarily owing to hemorrhage and/or infection. Considering 
smaller uterine blood supply and amount of gestational tissues in the first trimester 
than those in near term, conservative management after cessation of fetal heart 
beats in cesarean scar pregnancy may have higher success rate, if possible, with 
close postpartum follow-up for at least several months.
8. Conclusion
The basic policy for the management of non-tubal ectopic pregnancy, such as 
CSP and cervical pregnancy, is termination of pregnancy and preservation of the 
uterus, and the method of treatment should be selected according to the gestational 
week, presence/absence of fetal heart beats, the blood hCG level, and abundance of 
the blood supply adjacent to villi or the gestational sac. Recent reviews and reports 
support an interventional or a combination of surgical and medical approaches for 
treatment of unruptured CSP and cervical pregnancy rather than medical approach 
alone. In a national cohort study, surgical management appears to be associated 
with a high success rate, low complication rate, and short posttreatment follow-up.
Massive hemorrhage reportedly occurs in some cases with spontaneous rupture 
or after evacuation of the uterus without an accurate diagnosis. In cases experienc-
ing massive hemorrhage, pressure hemostasis using balloon tamponade should first 
be performed. If such hemostasis proves to be ineffective, surgical excision or TAE 
should be selected next. If balloon tamponade or TAE is successful in controlling 
hemorrhage, conservative treatment is also a feasible option. In cases with coagu-
lopathy, the blood fibrinogen level is often <100 mg/dL. Therefore, the treatment 
of coagulopathy should be performed by combined administration of concentrated 
coagulation factors (fibrinogen concentrate and cryoprecipitate) and fresh-frozen 
plasma promptly to obtain a blood fibrinogen level of at least 150–200 mg/dL.
Recently, a minimally invasive hemostatic strategy in obstetrics, which aims to 
preserve uterine function and enhance the safety of subsequent pregnancies, has 
been developed. Therefore, we should reconsider uterus-preserving hemostatic 
D&C alone 
(n:6)
MTX + TAE + D&C (n:21) P-value
Blood transfusion/>2500 mL blood loss 83.3% 9.5% 0.001
(5/6) (2/21)
Wedge resection/hysterectomy 50.0% 0% 0.007
(3/6) (0/21)
Hospital stay (days) 15.5 + 10.4 9.6 + 8.4 0.163
Combined procedures (MTX + TAE + D&C) yielded satisfactory results with a decreased volume of blood loss, no 
additional surgical treatment, and a high cure rate, compared with D&C alone.
Table 4. 
Comparison of outcome and additional treatment between D&C alone and methotrexate + transcatheter 
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strategies for critical hemorrhage and management of non-tubal ectopic pregnancy 
under these circumstances by using safe and minimally invasive treatment modali-
ties. Moreover, if early detection of CSP is possible, more minimally invasive treat-
ment might be another option of treatment such as double balloon conservative 
therapy or hysteroscopic resection without chemotherapy. Conservative therapy 
without chemotherapy and surgical therapy may be the other option. They were just 
followed up closely in outpatient clinic after cessation of fetal heart beats by local 
injection of KCl.
The optimal treatment of CSP and cervical pregnancy is still unclear at present. 
Further evaluation of several therapies and hemostatic techniques by treating a 
large number of patients is necessary.
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